Achieve Life Sciences (ACHV) to Release Quarterly Earnings on Tuesday

Achieve Life Sciences (NASDAQ:ACHV) is expected to be releasing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Achieve Life Sciences to post earnings of ($0.30) per share for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings results on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Stock Performance

Shares of ACHV stock traded up $0.05 on Tuesday, hitting $4.44. The company had a trading volume of 282,187 shares, compared to its average volume of 926,465. The firm has a market cap of $236.34 million, a P/E ratio of -3.42 and a beta of 2.25. The company has a 50-day moving average price of $3.92 and a 200-day moving average price of $4.41. The company has a quick ratio of 4.39, a current ratio of 4.39 and a debt-to-equity ratio of 0.52. Achieve Life Sciences has a twelve month low of $2.00 and a twelve month high of $6.03.

Hedge Funds Weigh In On Achieve Life Sciences

Institutional investors and hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. increased its stake in shares of Achieve Life Sciences by 54.7% in the 3rd quarter. Raymond James Financial Inc. now owns 456,372 shares of the biopharmaceutical company’s stock valued at $1,438,000 after purchasing an additional 161,314 shares in the last quarter. Two Sigma Investments LP purchased a new position in shares of Achieve Life Sciences in the 3rd quarter valued at about $1,383,000. Squarepoint Ops LLC increased its stake in shares of Achieve Life Sciences by 2,676.5% in the 3rd quarter. Squarepoint Ops LLC now owns 373,079 shares of the biopharmaceutical company’s stock valued at $1,175,000 after purchasing an additional 359,642 shares in the last quarter. State Street Corp increased its stake in shares of Achieve Life Sciences by 6.3% in the 4th quarter. State Street Corp now owns 234,257 shares of the biopharmaceutical company’s stock valued at $1,164,000 after purchasing an additional 13,873 shares in the last quarter. Finally, Shay Capital LLC increased its stake in shares of Achieve Life Sciences by 10.1% in the 2nd quarter. Shay Capital LLC now owns 292,647 shares of the biopharmaceutical company’s stock valued at $661,000 after purchasing an additional 26,913 shares in the last quarter. Hedge funds and other institutional investors own 33.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ACHV. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Achieve Life Sciences in a report on Thursday, April 16th. Canaccord Genuity Group set a $13.00 price objective on Achieve Life Sciences and gave the company a “buy” rating in a report on Monday, April 20th. Finally, Weiss Ratings raised Achieve Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $14.67.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.